A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection

Gilead Sciences

Status and phase: Completed; Phase 1

Conditions: Hepatitis B

Treatments: Drug: Multiple Ascending Dose (MAD) Cohorts GS-9620; Drug: Single Ascending Dose (SAD) Cohorts GS-9620

Study type: Interventional

Funder types: Industry

Identifiers

NCT01590654

GS-US-283-0102

Details and patient eligibility

About

Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Dose escalation or repetition will be governed by pre-specified safety and activity rules. Subjects will be confined on days 1-3 and/or days 8-10. Follow-up visits are required periodically through day 43. Subjects with sustained reductions in HbsAg will be requested to return for additional follow-up follow-up visits at 3 and 6 months post last dose. Study procedures involve blood draws for pharmacokinetic, pharmacodynamic, virologic, and safety assessments

Enrollment: 51 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Chronic HBV infection for ≥ 6 months
• Currently on treatment with at least 1 HBV approved oral drug (i.e. lamivudine, telbivudine, entecavir, adefovir, tenofovir) ≥ 3 months prior to screening
• HBsAg ≥ 250 IU/mL
• HBV DNA at below the level of quantitation (BLQ; to be confirmed at screening)
• Absence of extensive bridging fibrosis (Metavir 3 or greater)or cirrhosis
• Creatinine clearance ≥ 70 mL/min

Exclusion criteria

• Co-infection with hepatitis C virus (HCV), hepatitis D virus (HDV), or HIV
• History of Gilberts disease
• Laboratory parameters not within defined thresholds for leukopenia, neutropenia, anemia, thrombocytopenia, thyroid-stimulating hormone (TSH), or other evidence of hepatic decompensation
• Diagnosis of autoimmune disease, poorly controlled diabetes mellitus, significant psychiatric illness, severe chronic obstructive pulmonary disease (COPD), malignancy, hemoglobinopathy, retinal disease, or patients who are immunosuppressed
• Evidence of hepatocellular carcinoma

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

51 participants in 8 patient groups

0.3mg GS-9620

Experimental group

Treatment:

Drug: Single Ascending Dose (SAD) Cohorts GS-9620

1mg GS-9620

Experimental group

Treatment:

Drug: Single Ascending Dose (SAD) Cohorts GS-9620

2mg GS-9620

Experimental group

Treatment:

Drug: Single Ascending Dose (SAD) Cohorts GS-9620

4mg GS-9620

Experimental group

Treatment:

Drug: Single Ascending Dose (SAD) Cohorts GS-9620

0.3mg GS-9620 QW x 2 doses

Experimental group

Treatment:

Drug: Multiple Ascending Dose (MAD) Cohorts GS-9620

1mg GS-9620 QW x 2 doses

Experimental group

Treatment:

Drug: Multiple Ascending Dose (MAD) Cohorts GS-9620

2mg GS-9620 QW x 2 doses

Experimental group

Treatment:

Drug: Multiple Ascending Dose (MAD) Cohorts GS-9620

4mg GS-9620 QW x 2 doses

Experimental group

Treatment:

Drug: Multiple Ascending Dose (MAD) Cohorts GS-9620